Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
NCT02092922Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of filanesib in multiple myeloma (MM), sponsored by Pfizer. Primary endpoint: Objective Response Rate in patients with low Baseline alpha 1-acid glycoprotein (AAG) at 2 years. Started May 2014; status: completed.
02
Drugs
filanesib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02092922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092922.